AwesomeCapital: Royalty Pharma to buy 3%-4% royalty in AstraZeneca Phase 3 ATTR-CM drug cliramitug for up to $425M

Wednesday, July 22, 2026

Royalty Pharma to buy 3%-4% royalty in AstraZeneca Phase 3 ATTR-CM drug cliramitug for up to $425M

Transaction includes $125 million upfront payment plus additional milestone-based payments to Neurimmune.
https://finviz.com/stock?t=RPRX&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)